Article

HHS challenges Stark II lithotripsy judgment

Washington-Although urologists were victorious in a recent courtdecision excluding lithotripsy from the Stark II rule, the U.S. Departmentof Health and Human Services said it will appeal the ruling.

Related Videos
Yahir A. Santiago-Lastra, MD, answers a question during a Zoom video interview
1 expert is featured in this series.
1 expert is featured in this series.
Woman talking with a doctor | Image Credit: © Liudmila Dutko - stock.adobe.com
2 experts are featured in this series.
2 experts are featured in this series.
Rebecca A. Campbell, MD, answers a question during a Zoom video interview
Related Content
Enrollment progresses in study for cisplatin-induced hearing loss in testicular cancer
May 14th 2025

Enrollment progresses in study for cisplatin-induced hearing loss in testicular cancer

Hannah Clarke
ACOU085 will be administered in 1 ear, with a matching placebo injection in the respective contralateral middle ear.
Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25
May 4th 2025

Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25

Amy M. Pearlman, MD Kevin C. Zorn, MD, FRCSC, FACS
Urologists discuss innovative BPH treatments, emphasizing personalized care, and the importance of ejaculatory preservation.
Conceptual image for prostate cancer treatment, 3D illustration showing destruction of a tumor inside prostate gland | Image Credit: © Dr_Microbe - stock.adobe.come
May 13th 2025

MRI and focal therapy may enable men on AS to safely delay surgery or radiation

Hannah Clarke
Use of focal therapy was shown to prolong the duration of active surveillance.
Pearls & Perspectives: Understanding and addressing priapism, with Serge Carrier, MD, and Gregory Broderick, MD
May 2nd 2025

Pearls & Perspectives: Understanding and addressing priapism, with Serge Carrier, MD, and Gregory Broderick, MD

Amy M. Pearlman, MD
Experts discuss urgent priapism management strategies, emphasizing timely intervention and collaboration for optimal patient outcomes.
Disitamab vedotin plus toripalimab extends PFS, OS in HER2-positive la/mUC
May 12th 2025

Disitamab vedotin plus toripalimab extends PFS, OS in HER2-positive la/mUC

Hannah Clarke
The phase 3 RC48-C016 trial met its primary end points.
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
May 11th 2025

We got a little MIST-y at this year’s AUA Annual Meeting

Garrett D. Pohlman, MD
Urologist Garrett D. Pohlman, MD, reflects on the benign prostatic hyperplasia offerings from the 2025 American Urological Association Annual Meeting.
© 2025 MJH Life Sciences

All rights reserved.